Stock Analysis of Arbutus Biopharma Corp (ABUS) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code ABUS
Close 2.98
Change 0.090 / 3.11 %
Volume 746123
Vol Change 319087 / 74.72 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthBullish
Growth Index Very Low Growth Stock
Value Index Poor Value Stock
Profitability Index Poor Profitability Stock
Stability Index Low Stability Stock


Fundamental View of Arbutus Biopharma Corp
PE (TTM)

-1668.34

Very Poor
Price / Book

1003.07

Very Poor
Price / Sales

9556.40

Very Poor
Piotroski F Score

1.0

Very Poor
Market Cap

562376 K

Enterprise Value

436798 K

ROA (TTM)

-45.28

Very Poor
ROE (TTM)

-60.12

Very Poor
Net Margin (TTM)

-572.81

Very Poor
Revenue

43.00 %

22241.00 K
Net Profit

8.66 %

-75469.00 K
Debt to Equity

0.0040

Excellent
Altman Z Score

-4.23

Very Poor
Quick Ratio

5.95

Very Good
Cash Ratio

5.60

Very Good


Highs/Lows of Arbutus Biopharma Corp
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week2.88 3.47 % 1.54 % 3.012.80517-May-2415-May-24
Two Week2.71 9.96 % 3.42 % 3.012.717-May-2406-May-24
One Month2.78 7.19 % 5.60 % 3.012.6317-May-2402-May-24
Three Month2.9 2.76 % 5.95 % 3.292.305-Apr-2403-Apr-24
Six Months1.86 60.22 % 17.48 % 3.291.7905-Apr-2428-Nov-23
One year2.52 18.25 % 27.52 % 3.291.6905-Apr-2423-Oct-23
Two year2.41 23.65 % 29.70 % 3.291.6905-Apr-2423-Oct-23
Five year2.4 24.17 % 85.46 % 3.290.821405-Apr-2421-Oct-19
Ten year11.2 73.39 % 182.41 % 29.930.821403-Oct-1421-Oct-19


Technical View of Arbutus Biopharma Corp
RSI

61.50

Neutral
MACD

0.0371

Bullish
ADX

13.43

Neutral
Super Trend

2.62

Mild Bullish
Williams %R

-7.89

Mild Bearish
CCI

161.49

Mild Bearish


EMA 5

2.90

Strong Bullish
EMA 15

2.85

Neutral
EMA 50

2.77

Strong Bullish
EMA 100

2.65

Strong Bullish
SMA 100

2.67

Strong Bullish
SMA 200

2.32

Strong Bullish
SMA 5 / 20

2.89 / 2.80

Mild Bullish
SMA 15 / 50

2.82 / 2.76

Bullish
SMA 50 / 200

2.76 / 2.32

Mild Bullish




Charts of Arbutus Biopharma Corp


Returns of Arbutus Biopharma Corp with Peers
Period / StockABUSTHRDOFIXOLMA
1 Week3.47%16.51%2.46%5.58%
1 Mth7.19%22.92%15.38%-8.12%
3 Mth2.76%37.69%8.77%-34.36%
6mth60.22%112.33%42.99%-38.15%
1 Year18.25%218.00%-20.38%41.58%
2 Year23.65%--47.31%347.27%
5 Years24.17%--71.28%-
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Arbutus Biopharma Corp with Peers
Ratio / StockABUSTHRDOFIXOLMA
PE-1668.348640.11-5.14-4.86
P/B1003.07503.491.042.19
ROA-45.285.66-13.59-41.16
ROE-60.125.83-20.17-45.08
Debt To Equity0.00400.00280.1650.0039
Revenue22241.00 K
43.00 % 		0
% 		668455 K
45.09 % 		0
%
Net Income-75469.00 K
8.66 % 		-35478.00 K
200.92 % 		-136283.00 K
590.08 % 		-96062.00 K
8.33 %


Technicals of Arbutus Biopharma Corp with Peers
Technical / StockABUSTHRDOFIXOLMA-
ADX13.4328.6417.8723.39
CMF0.02120.0289-0.138-0.0199
MFI47.2875.9970.7251.32
RSI61.5070.8262.2844.68
MACD Abv SignalTrueTrueTrueFalse
Price Above 50 MATrueTrueTrueFalse-
Price Above 200 MATrueTrueTrueFalse-


About : Arbutus Biopharma Corp

Address : 701 Veterans Circle, Warminster, PA, United States, 18974
Tel : 267 469 0914
URL : https://www.arbutusbio.com
Code : ABUS, ISIN : CA03879J1003, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 03_Aug_2015
Employee Count : 73

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.


Note : All Data Generated at the End of Trading Hours (EOD Data)